Cardiometabolic Early Intervention Study
- Conditions
- Type 2 diabetes mellitus, ischaemic heart disease, acute coronary syndrome.Nutritional, Metabolic, Endocrine
- Registration Number
- ISRCTN96975795
- Lead Sponsor
- niversity of Lincoln
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 1200
1. 18 years and older (no upper age limit)
2. Male or female
3. Type 1 acute myocardial infarction (AMI) (both ST elevation and Non-ST elevation MI) as per the 4th Universal definition of myocardial infarction
4. Known or newly diagnosed type 2 Diabetes Mellitus
5. Successful discharge from the hospital after the index event
1. Type 1 DM (as the safety of SGLT2i in this group is still not known and therefore, not recommended currently)
2. Non-diabetics
3. Prediabetics
4. Current pregnancy (contraindication for SGLT2i use)
5. Breastfeeding (contraindication for SGLT2i use)
6. End-stage kidney with a life expectancy of fewer than 6 months, including GFR,15 ml/min/1.73 m2 (making SGLT2i contraindicated)
7. End-stage liver disease life expectancy of less than 6 months
8. Death in hospital at index event (First heart attack for the duration of the study)
9. Non-cardiovascular conditions, such as advanced malignancy, that will result in a life expectancy of less than 6 months
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method